Search

Displaying results 1981 - 1990 of 10000 in total
  1. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L42245] In June 2022, the European Medicines Agency approved mosunetuzumab for the treatment of adult patients with relapsed or refractory (R/R) FL who have received at least two prior systemic therapies … [L42245] In January 2023, the FDA granted accelerated approval to intravenous mosunetuzumab based on response rate.

  2. Drug

    rCFP-10

    go.drugbank.com/drugs/DB21907
    Approved

    rCFP-10 is a recombinant culture filtrate protein of _Mycobacterium tuberculosis_ used as an ingredient in the diagnostic agent SIILTIBCY along with [rdESAT-6].[L53638]

  3. Drug

    Pyrantel

    go.drugbank.com/drugs/DB11156
    ApprovedVet approved

    Pyrantel is on the World Health Organization's List of Essential Medicines, which are the safest and most effective medicines required in a functioning health system [L1901], [L1902]. … Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use as an anthelmintic drug

  4. Drug

    Besilesomab

    go.drugbank.com/drugs/DB13979
    Approved

    Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the … Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis

  5. Drug

    Anisotropine methylbromide

    go.drugbank.com/drugs/DB00517
    Approved

    action on the bile ducts and gallbladder. … Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.

  6. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications.

    Categories: Drugs Used in Diabetes
  7. Drug

    Testosterone propionate

    go.drugbank.com/drugs/DB01420
    ApprovedInvestigationalVet approvedWithdrawn

    Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160] … [T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974.

    Mixtures: TEST - COMP 250Products: Malogen In Oil Liq 100mg/ml
  8. Drug

    Phloxine B

    go.drugbank.com/drugs/DB13911
    ApprovedWithdrawn

    Phloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™. … It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.

  10. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular